Literature DB >> 3180054

Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma.

N Schek1, B L Hall, O J Finn.   

Abstract

To identify and characterize genes, the products of which play a role in pancreatic adenocarcinoma, we constructed a complementary DNA (cDNA) library using mRNA from the pancreatic adenocarcinoma cell line HPAF, grown as a nude mouse tumor. Through differential screening, we identified a cDNA clone, pII5B, that is homologous to an mRNA expressed at significantly higher levels in HPAF cells than in normal human pancreas. The pII5B cDNA was homologous to the 3'-untranslated region of glyceraldehyde-3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12)mRNA. Partial sequencing of several HPAF tumor GAPDH cDNA clones revealed no significant differences from previously published GAPDH cDNA sequences. Increased levels of GAPDH mRNA, relative to actin mRNA levels, were found in six pancreatic adenocarcinoma cell lines and two nude mouse tumors, when compared to normal pancreas. Enolase and glucose transporter mRNA levels were also increased in HPAF cells and nude mouse tumor, suggesting a general increase in expression of genes associated with glycolysis in pancreatic adenocarcinoma. Levels of GAPDH protein were elevated in nude mouse tumors and fresh human pancreatic adenocarcinomas compared to normal pancreas. High GAPDH levels may be characteristic of human adenocarcinomas, since colon adenocarcinomas also exhibited high levels of GAPDH compared to normal colon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180054

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Regulation of bladder muscarinic receptor subtypes by experimental pathologies.

Authors:  M R Ruggieri; A S Braverman
Journal:  Auton Autacoid Pharmacol       Date:  2006-07

2.  Muscarinic receptor transcript and protein density in hypertrophied and atrophied rat urinary bladder.

Authors:  Alan S Braverman; Michael R Ruggieri
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

3.  UBC and YWHAZ as suitable reference genes for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell lines.

Authors:  Siang Ling Chua; Wei Cun See Too; Boon Yin Khoo; Ling Ling Few
Journal:  Cytotechnology       Date:  2011-08-18       Impact factor: 2.058

4.  Selection of suitable reference genes for quantitative real-time PCR in apoptosis-induced MCF-7 breast cancer cells.

Authors:  Eloise Ferreira; Marianne J Cronjé
Journal:  Mol Biotechnol       Date:  2012-02       Impact factor: 2.695

Review 5.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

6.  Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view.

Authors:  R K Kasperk; K P Riesener; K Wilms; V Schumpelick
Journal:  World J Surg       Date:  2001-09       Impact factor: 3.352

7.  Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Authors:  Uzoma K Iheagwara; Pamela L Beatty; Phu T Van; Ted M Ross; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2013-12-05       Impact factor: 11.151

Review 8.  Novel insight into the role of GAPDH playing in tumor.

Authors:  Chunmei Guo; Shuqing Liu; Ming-Zhong Sun
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 9.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

10.  MALDI profiling of human lung cancer subtypes.

Authors:  Angelo Gámez-Pozo; Iker Sánchez-Navarro; Manuel Nistal; Enrique Calvo; Rosario Madero; Esther Díaz; Emilio Camafeita; Javier de Castro; Juan Antonio López; Manuel González-Barón; Enrique Espinosa; Juan Angel Fresno Vara
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.